Epidemiologic, Virologic, and Host Genetic Factors of Norovirus Outbreaks in Long-term Care Facilities.

BACKGROUND In the Unites States, long-term care facilities (LTCFs) are the most common setting for norovirus outbreaks. These outbreaks provide a unique opportunity to better characterize the viral and host characteristics of norovirus disease. METHODS We enrolled 43 LTCFs prospectively to study the epidemiology, virology, and genetic host factors of naturally occurring norovirus outbreaks. Acute and convalescent stool, serum, and saliva samples from cases, exposed and nonexposed controls were collected. Norovirus infection was confirmed using quantitative polymerase chain reaction testing of stool samples or 4-fold increase in serum antibody titers. The presence of histo-blood group antigens (secretor, ABO, and Lewis type) was determined in saliva. RESULTS Sixty-two cases, 34 exposed controls, and 18 nonexposed controls from 10 norovirus outbreaks were enrolled. Forty-six percent of acute, 27% of convalescent case, and 11% of control stool samples tested norovirus positive. Outbreak genotypes were GII.4 (Den Haag, n = 3; New Orleans, n = 4; and Sydney, n = 2) and GI.1 (n = 1). Viral load in GII.4 Sydney outbreaks was significantly higher than in outbreaks caused by other genotypes; cases and controls shed similar amounts of virus. Forty-seven percent of cases shed virus for ≥ 21 days. Symptomatic infections with GII.4 Den Haag and GII.4 New Orleans were detected among nonsecretor individuals. CONCLUSIONS Almost half of all symptomatic individuals shed virus for at least 21 days. Viral load was highest in GII.4 viruses that most recently emerged; these viruses also infect the nonsecretor population. These findings will help to guide development of targeted prevention and control measures in the elderly.

[1]  D. Graham,et al.  Mucosal and Cellular Immune Responses to Norwalk Virus. , 2015, The Journal of infectious diseases.

[2]  P. Szilagyi,et al.  Innate Susceptibility to Norovirus Infections Influenced by FUT2 Genotype in a United States Pediatric Population. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  C. Moe,et al.  Disease course and viral shedding in experimental Norwalk virus and Snow Mountain virus infection , 2014, Journal of medical virology.

[4]  P. Teunis,et al.  Shedding of norovirus in symptomatic and asymptomatic infections , 2014, Epidemiology and Infection.

[5]  Marion Koopmans,et al.  Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysis. , 2014, The Lancet. Infectious diseases.

[6]  J. Le Pendu,et al.  Increase in genogroup II.4 norovirus host spectrum by CagA-positive Helicobacter pylori infection. , 2014, The Journal of infectious diseases.

[7]  Jan Vinjé,et al.  Advances in Laboratory Methods for Detection and Typing of Norovirus , 2014, Journal of Clinical Microbiology.

[8]  D. Graham,et al.  Determination of the 50% human infectious dose for Norwalk virus. , 2014, The Journal of infectious diseases.

[9]  Jan Vinjé,et al.  Norovirus Disease in the United States , 2013, Emerging infectious diseases.

[10]  L. Gould,et al.  Acute Gastroenteritis Surveillance through the National Outbreak Reporting System, United States , 2013, Emerging infectious diseases.

[11]  J. Vinjé,et al.  Effects and Clinical Significance of GII.4 Sydney Norovirus, United States, 2012–2013 , 2013, Emerging infectious diseases.

[12]  D. Sano,et al.  Histo-Blood Group Antigen-Like Substances of Human Enteric Bacteria as Specific Adsorbents for Human Noroviruses , 2013, Journal of Virology.

[13]  J. Vinjé,et al.  Emergence of New Norovirus Strain GII.4 Sydney — United States, 2012 , 2013, MMWR. Morbidity and mortality weekly report.

[14]  D. Bernstein,et al.  Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans. , 2012, The Journal of infectious diseases.

[15]  A. Curns,et al.  Hospitalizations and mortality associated with norovirus outbreaks in nursing homes, 2009-2010. , 2012, JAMA.

[16]  D. Partridge,et al.  Lessons from a large norovirus outbreak: impact of viral load, patient age and ward design on duration of symptoms and shedding and likelihood of transmission. , 2012, The Journal of hospital infection.

[17]  P. Teunis,et al.  Nosocomial transmission of norovirus is mainly caused by symptomatic cases. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  M. Nei,et al.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. , 2011, Molecular biology and evolution.

[19]  J. Vinjé,et al.  Impact of an emergent norovirus variant in 2009 on norovirus outbreak activity in the United States. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  J. Vinjé,et al.  Novel Surveillance Network for Norovirus Gastroenteritis Outbreaks, United States , 2011, Emerging infectious diseases.

[21]  J. Vinjé,et al.  Updated norovirus outbreak management and disease prevention guidelines. , 2011, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[22]  P. Pothier,et al.  Qualitative and Quantitative Analysis of the Binding of GII.4 Norovirus Variants onto Human Blood Group Antigens , 2011, Journal of Virology.

[23]  K. Mizuta,et al.  Duration of norovirus excretion and the longitudinal course of viral load in norovirus-infected elderly patients. , 2010, The Journal of hospital infection.

[24]  J. Vinjé,et al.  Epidemiological and genetic characteristics of norovirus outbreaks in long-term care facilities, 2003–2006 , 2010, Epidemiology and Infection.

[25]  L. Svensson,et al.  Norovirus Gastroenteritis Outbreak with a Secretor-independent Susceptibility Pattern, Sweden , 2010, Emerging infectious diseases.

[26]  R. Glass,et al.  Molecular Epidemiology of Genogroup II-Genotype 4 Noroviruses in the United States between 1994 and 2006 , 2009, Journal of Clinical Microbiology.

[27]  Reem Abu Mallouh,et al.  The G428A Nonsense Mutation in FUT2 Provides Strong but Not Absolute Protection against Symptomatic GII.4 Norovirus Infection , 2009, PloS one.

[28]  L. Svensson,et al.  Genetic susceptibility to symptomatic norovirus infection in Nicaragua , 2009, Journal of medical virology.

[29]  D. Graham,et al.  Norwalk Virus Shedding after Experimental Human Infection , 2008, Emerging infectious diseases.

[30]  P. Teunis,et al.  Norwalk virus: How infectious is it? , 2008, Journal of medical virology.

[31]  P. White,et al.  Norovirus Excretion in an Aged-Care Setting , 2008, Journal of Clinical Microbiology.

[32]  W. Leung,et al.  Fecal Viral Load and Norovirus-associated Gastroenteritis , 2006, Emerging infectious diseases.

[33]  B. Wahrén,et al.  A nonsense mutation (428G→A) in the fucosyltransferase FUT2 gene affects the progression of HIV-1 infection , 2006, AIDS.

[34]  K. Hedlund,et al.  A Homozygous Nonsense Mutation (428G→A) in the Human Secretor (FUT2) Gene Provides Resistance to Symptomatic Norovirus (GGII) Infections , 2005, Journal of Virology.

[35]  Xi Jiang,et al.  Human susceptibility and resistance to Norwalk virus infection , 2003, Nature Medicine.

[36]  R. Baric,et al.  Binding of Norwalk Virus-Like Particles to ABH Histo-Blood Group Antigens Is Blocked by Antisera from Infected Human Volunteers or Experimentally Vaccinated Mice , 2002, Journal of Virology.

[37]  J. Le Pendu,et al.  Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals , 2002, Gastroenterology.

[38]  William R. Taylor,et al.  The rapid generation of mutation data matrices from protein sequences , 1992, Comput. Appl. Biosci..